Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Bismuth-Carrying Nanotubes Show Potential for CT Imaging

By BiotechDaily International staff writers
Posted on 24 Sep 2013
Image: An X-ray image of unlabeled mesenchymal stem cells in test tubes shows the dramatic difference between those tagged with nanotubes that don't include bismuth (left) and those that do (right). The technique developed at Rice University shows promise for tracking live stem cells in the body (Photo courtesy of Eladio Rivera, Rice University).
Image: An X-ray image of unlabeled mesenchymal stem cells in test tubes shows the dramatic difference between those tagged with nanotubes that don't include bismuth (left) and those that do (right). The technique developed at Rice University shows promise for tracking live stem cells in the body (Photo courtesy of Eladio Rivera, Rice University).
Scientists have found a way to capture bismuth in a nanotube cage to tag stem cells for X-ray tracking.

Bismuth is perhaps best known as the active element in a popular stomach-settling medicine and is used in medical applications and cosmetics. Chemist Dr. Lon Wilson and his colleagues are inserting bismuth compounds into single-walled carbon nanotubes to make a more effective contrast agent for computed tomography (CT) scanners.

The study conducted by Rice University’s (Houston, TX, USA) chemist Dr. Lon Wilson and collaborators at the University of Houston (TX, USA), St. Luke’s Episcopal Hospital (Houston, TX, USA), and the Texas Heart Institute (Houston, USA) was published in the Journal of Materials Chemistry B. This is not the first time bismuth has been studied for CT scans, and Dr. Wilson’s lab has been experimenting for years with nanotube-based contrast agents for magnetic resonance imaging (MRI) scanners. But this is the first time anyone has combined bismuth with nanotubes to image individual cells, he said.

“At some point, we realized no one has ever tracked stem cells, or any other cells that we can find, by CT,” Dr. Wilson stated. “CT is much faster, cheaper, and more convenient, and the instrumentation is much more widespread [than MRI]. So we thought if we put bismuth inside the nanotubes and the nanotubes inside stem cells, we might be able to track them in vivo in real time.”

Recent research validates their hypothesis. In tests using pig bone marrow-derived mesenchymal stem cells, Dr. Wilson and lead author Dr. Eladio Rivera, a former postdoctoral researcher at Rice, found that the bismuth-filled nanotubes, which they call Bi@US-tubes, produce CT images far brighter than those from typical iodine-based contrast agents. “Bismuth has been thought of before as a CT contrast agent, but putting it in nanotube capsules allows us to get them inside cells in high concentrations,” Dr. Wilson said. “That lets us take an X-ray image of the cell.”

The capsules are synthesized from a chemical process that cuts and purifies the nanotubes. When the tubes and bismuth chloride are mixed in a solution, they combine over time to form Bi@US-tubes. The nanotube capsules are between 20- and 80-nm long and about 1.4-nm in diameter. “They’re small enough to diffuse into the cell, where they then aggregate into a clump about 300 nanometers in diameter,” Dr. Wilson stated. “We think the surfactant used to suspend them in biological media is stripped off when they pass through the cell membrane. The nanotubes are lipophilic, so when they find each other in the cell they stick together.”

Dr. Wilson reported that his team’s studies showed stem cells readily absorb Bi@US-tubes without affecting their function. “The cells adjust over time to the incorporation of these chunks of carbon and then they go about their business,” he said.

Bi@US-tubes have distinct advantages over typically used iodine-based contrast agents, according to Dr. Wilson. “Bismuth is a heavy element, down near the bottom of the periodic table, and more effective at diffracting X-rays than almost anything else you could use,” he said.

The agent can generate high contrast in very small concentrations once the bismuth is encapsulated in the nanotubes. The nanotube surfaces can be modified to improve biocompatibility and their capability to target specific types of cells. They can also be adapted for use with MRI, positron emission tomography (PET), and electron paramagnetic resonance imaging systems.

The Rice lab is working to double the amount of bismuth in each nanotube. “Bismuth ions appear to get into the nanotubes by capillary action, and we think we can improve on the process to at least double the contrast, maybe more,” Dr. Wilson concluded. “Then we would like to combine both bismuth and gadolinium into one nanotube to produce a bimodal contrast agent that can be tracked with both MRI and CT scanners.”

Related Links:
Rice University
University of Houston
Texas Heart Institute


comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.